Skip to main content
Top
Published in: Tumor Biology 3/2013

01-06-2013 | Research Article

A support vector machine model for predicting non-sentinel lymph node status in patients with sentinel lymph node positive breast cancer

Authors: Xiaowen Ding, Shangnao Xie, Jie Chen, Wenju Mo, Hongjian Yang

Published in: Tumor Biology | Issue 3/2013

Login to get access

Abstract

This study aimed to investigate the accuracy and feasibility of support vector machine (SVM) modeling in predicting non-sentinel lymph node (NSLN) status in patients with SLN-positive breast cancer. Clinicopathological data were collected from 201 cases with sentinel lymph node biopsy breast cancer and included patient age, tumor size, histological type and grade, vascular invasion, estrogen receptor status, progesterone receptor status, CerbB2 status, size and number of positive SLNs, number of negative SLNs, and positive SLN membrane invasion. Feature vector selection was based on a combination of statistical filtration and model-dependent screening. The arbitrary combination with the smallest p value for SVM input was selected, the predicative results of the model were evaluated by a 10-fold cross validation, and a training model was established. Using SLN-positive patients as a double-blind test set, 85 patients were input into the model to analyze its sensitivity and specificity. The combination with the highest cross-validation accuracy was selected for the SVM model and consisted of the following: the number and size of positive SLNs, the number of negative SLNs, and the membrane invasion of positive SLNs. The training accuracy of the model established with the four variables was 92 %, and its cross-validation veracity was 87.6 %. The accuracy of an 85-patient double-blind test of the SVM model was 91.8 %. In conclusion, this SVM model is an accurate and feasible method for the prediction of NSLN status in SLN-positive breast cancer and is conducive to guide clinical treatment.
Literature
1.
go back to reference Nakhlis F, Golshan M. Bevacizumab: where do we go from here in breast cancer? Transl Cancer Res. 2012;1(1):55–6. Nakhlis F, Golshan M. Bevacizumab: where do we go from here in breast cancer? Transl Cancer Res. 2012;1(1):55–6.
2.
go back to reference Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25(1):10–21.PubMed Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25(1):10–21.PubMed
3.
go back to reference Zhang BN, Cao XC, Chen JY, Chen J, Fu L, Hu XC, et al. Guidelines on the diagnosis and treatment of breast cancer (2011 edition). Gland Surg. 2012;1(1):39–61. Zhang BN, Cao XC, Chen JY, Chen J, Fu L, Hu XC, et al. Guidelines on the diagnosis and treatment of breast cancer (2011 edition). Gland Surg. 2012;1(1):39–61.
4.
go back to reference Rashid OM, Takabe K. The evolution of the role of surgery in the management of breast cancer lung metastasis. J Thorac Dis. 2012;4(4):420–4.PubMed Rashid OM, Takabe K. The evolution of the role of surgery in the management of breast cancer lung metastasis. J Thorac Dis. 2012;4(4):420–4.PubMed
5.
go back to reference Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–53.PubMedCrossRef Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–53.PubMedCrossRef
6.
go back to reference Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(9):599–609.PubMedCrossRef Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(9):599–609.PubMedCrossRef
7.
go back to reference Fan F. Sentinel lymph node micrometastases and isolated tumor cells in breast cancer: an evolving field. Gland Surg. 2012;1(1):5–6. Fan F. Sentinel lymph node micrometastases and isolated tumor cells in breast cancer: an evolving field. Gland Surg. 2012;1(1):5–6.
8.
go back to reference Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23(19):4312–21.PubMedCrossRef Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23(19):4312–21.PubMedCrossRef
9.
go back to reference Bernet L, Cano R. Metastatic sentinel node and axillary lymphadenectomy revisited. Gland Surg. 2012;1(1):7–8. Bernet L, Cano R. Metastatic sentinel node and axillary lymphadenectomy revisited. Gland Surg. 2012;1(1):7–8.
10.
go back to reference McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008;26(32):5213–9.PubMedCrossRef McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008;26(32):5213–9.PubMedCrossRef
11.
go back to reference Nelson V, Rademaker A, Kaklamani V. Paradigm of polyendocrine therapy in endocrine responsive breast cancer: the role of fulvestrant. Chin Clin Oncol. 2013;2(1):10. Nelson V, Rademaker A, Kaklamani V. Paradigm of polyendocrine therapy in endocrine responsive breast cancer: the role of fulvestrant. Chin Clin Oncol. 2013;2(1):10.
12.
go back to reference Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111–8.PubMedCrossRef Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111–8.PubMedCrossRef
13.
go back to reference Shah-Khan M, Boughey JC. Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 Trial. Cancer Control. 2012;19(4):267–76.PubMed Shah-Khan M, Boughey JC. Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 Trial. Cancer Control. 2012;19(4):267–76.PubMed
14.
go back to reference Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18(13):2553–9.PubMed Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18(13):2553–9.PubMed
15.
go back to reference Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997;226(3):271–6.PubMedCrossRef Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997;226(3):271–6.PubMedCrossRef
16.
go back to reference Kamath VJ, Giuliano R, Dauway EL, Cantor A, Berman C, Ku NN, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg. 2001;136(6):688–92.PubMedCrossRef Kamath VJ, Giuliano R, Dauway EL, Cantor A, Berman C, Ku NN, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg. 2001;136(6):688–92.PubMedCrossRef
17.
go back to reference Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140–51.PubMedCrossRef Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140–51.PubMedCrossRef
18.
go back to reference Barranger E, Coutant C, Flahault A, Delpech Y, Darai E, Uzan S. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat. 2005;91(2):113–9.PubMedCrossRef Barranger E, Coutant C, Flahault A, Delpech Y, Darai E, Uzan S. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat. 2005;91(2):113–9.PubMedCrossRef
19.
go back to reference Pal A, Provenzano E, Duffy SW, Pinder SE, Purushotham AD. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg. 2008;95(3):302–9.PubMedCrossRef Pal A, Provenzano E, Duffy SW, Pinder SE, Purushotham AD. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg. 2008;95(3):302–9.PubMedCrossRef
20.
go back to reference Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, et al. Bay Area SLN Study. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66.PubMedCrossRef Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, et al. Bay Area SLN Study. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66.PubMedCrossRef
21.
go back to reference Sattlecker M, Bessant C, Smith J, Stone N. Investigation of support vector machines and Raman spectroscopy for lymph node diagnostics. Analyst. 2010;135(5):895–901.PubMedCrossRef Sattlecker M, Bessant C, Smith J, Stone N. Investigation of support vector machines and Raman spectroscopy for lymph node diagnostics. Analyst. 2010;135(5):895–901.PubMedCrossRef
Metadata
Title
A support vector machine model for predicting non-sentinel lymph node status in patients with sentinel lymph node positive breast cancer
Authors
Xiaowen Ding
Shangnao Xie
Jie Chen
Wenju Mo
Hongjian Yang
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0683-5

Other articles of this Issue 3/2013

Tumor Biology 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine